Indocyanine green (ICG) is a near-infrared fluorescent dye. Protein-bound ICG can be excited by external light with a wavelength range of 750 ~ 810 nm and emits near-infrared light with a wavelength of about 840 nm. Its half-life in blood is about 3 ~ 5 minutes. After entering the blood and binding to protein, it is absorbed by liver cells, enters the intestine through the biliary tract, and is finally excreted with feces.
This product is the first indocyanine green injection in China that has passed the double consistency evaluation. With its high purity, low impurity content, and optimized storage conditions, ICG provides stable and reliable diagnosis and treatment options to the medical community.
Indications: Detection of choroidal neovascularization, macular lesions, intraocular tumors, and retinal vascular lesions; intraoperative staining of capsule and internal limiting membrane.
Advantages: Provides clear choroidal vascular images for accurate diagnosis. In cataract and retinal surgery, fluorescent staining helps identify membranes accurately, reducing complications.
Indications: Evaluation of liver reserve function, liver tumor development, liver segment identification, and bile leakage observation.
Advantages: Optimal method for evaluating liver reserve function with rapidity and safety. Fluorescence characteristics help identify liver structures clearly during surgery.
Indications: Accurate localization of tumors, image development of the lymphatic system, and assessment of blood supply.
Advantages: Intuitive judgment of targets enhances visibility during operations.
Offerings include research, development, production, and sales of high-end medical devices (fluorescence imaging series), fluorescence contrast agent drugs (ICG, targeted series), and core components (fluorescence CMOS camera modules, endoscopes). These products are utilized in over 500 large hospitals across China.
Focus is placed on core technologies such as molecular fluorescence, Raman spectroscopy, AI, computer-aided drug molecular design (CADD), and AI-assisted drug design. The mission is to become a global leader in molecular fluorescence technology through the synergy of medical devices and pharmaceuticals.
Recognized as a specialized "little giant" enterprise, holding 131 core invention patents and 7 US invention patents. Strategic partnerships have been established with international leading companies in Germany and Japan, with business reaching more than 10 overseas countries.